A clinical study to evaluate the feasibility and dose delivery accuracy of Volumetric-modulated Dynamic WaveArc therapy

A clinical study to evaluate the feasibility and dose delivery accuracy of Volumetric-modulated Dynamic WaveArc therapy - VMDWAT feasibility study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023870

Enrollment

Registered

2016-10-01

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer, brain tumor (skull-based tumor)

Interventions

Volumetric-modulated Dynamic WaveArc therapy (VMDWAT) is delivered to patients with prostate cancers and brain tumors (skull-based tumors).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Clinically diagnosed as prostate cancer or brain tumor (skull-based tumor) 2) ECOG-PS(performance status) = 0,1,2

Exclusion criteria

Exclusion criteria: 1) With severe coexisting diseases such as collagen disease, heart disease, respiratory disease and liver disease. 2) Psychotic disease 3) History of irradiation to the area where VMDWAT is considered to be delivered 4) Dose distribution of VMDWAT is inferior to that of conventional radiotherapy

Design outcomes

Primary

Measure	Time frame
The ratio of the patients who completed the treatment course	—

Secondary

Measure	Time frame
Incidence of acute adverse events, Incidence of severe acute adverse events	—

Countries

Japan

Contacts

Public ContactTakashi Mizowaki

Kyoto University Graduate School of Medicine Department of Radiation Oncology and Image-applied Therapy

mizo@kuhp.kyoto-u.ac.jp075-751-3762

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026